FIELD: immunology.
SUBSTANCE: disclosed is a bispecific antibody comprising a first antigen-binding portion which specifically binds to PD1 (protein 1 of planned cell death), and a second antigen-binding portion, which binds specifically to TIM3. Invention also discloses a polynucleotide, a vector, a host cell and a method for producing the antibody of the invention. In addition, a pharmaceutical composition, a method for inhibiting growth of tumor cells and use of an antibody for treating infections for preventing and treating cancer are described.
EFFECT: due to ability to bind both PD1, which is characterized by wide expression profile, and TIM-3 immune cells antigen, disclosed antibody can be used in treating a large number of diseases, including cancer.
29 cl, 14 dwg, 28 tbl, 18 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO PD1 AND LAG3 | 2018 |
|
RU2778805C2 |
| COMBINATION THERAPY BASED ON T-CELL-ACTIVATING BISPECIFIC ANTIGEN-BINDING MOLECULES AGAINST CD3 AND FOLATE RECEPTOR 1 (FOLR1) AND ANTAGONISTS BINDING TO PD-1 AXIS | 2015 |
|
RU2753902C2 |
| BIOSPECIFIC ANTIGEN-BINDING MOLECULES | 2012 |
|
RU2650775C2 |
| NEW BISPECIFIC ANTIGEN-BINDING MOLECULES WITH CAPABILITY OF SPECIFICALLY BINDING TO CD40 AND FAP | 2018 |
|
RU2766234C2 |
| MONOVALENT CARRIER MODULES ACROSS BLOOD-BRAIN BARRIER | 2014 |
|
RU2694659C2 |
| UNIVERSAL TRANSMITTER MODULES THROUGH THE HEMATOENCEPHALITIC BARRIER | 2014 |
|
RU2799436C1 |
| ANTIBODIES BINDING TO GPRC5D | 2019 |
|
RU2797268C2 |
| ANTIBODIES BINDING TO HLA-A2/WT1 | 2018 |
|
RU2815176C2 |
| ANTIBODIES TO LAG3 | 2018 |
|
RU2778053C2 |
| THEOPHYLLINE ANTIBODIES AND METHODS FOR THEIR APPLICATION | 2013 |
|
RU2630664C2 |
